Prostate cancer combo trial pulled before enrolling a single patient
NCT ID NCT06528210
First seen Nov 01, 2025 · Last updated Jun 06, 2026 · Updated 27 times
Summary
This study was designed to see if adding the immunotherapy drug pembrolizumab to standard hormone therapy and radiation could improve outcomes for men with high-risk prostate cancer that hasn't spread. The trial was withdrawn before any participants were enrolled, so no results are available. The goal was to find a more effective way to control the disease and reduce the chance of it returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.